glp-1 drugs and fatty liver Resmetirom agonists for MASH: complementary rather than exclusive American drugmakers pushed GLP1 therapies
Description
Results from clinical trials are years away, emphasized Dr
Theyre associated with a lower risk of several cancers, including pancreatic cancer and multiple myeloma
Novo shares, for instance, just fell to a four-year low following clinical trial results showing that its oral semaglutide failed to slow the progression of Alzheimers disease
doi: 10.1111/j.1463-1326.2011.01364.x 109 DunganKMPovedanoSTForstTGonzlezJGGAtissoCSeallsWet al
The combination produces better results than phentermine alone, typically 12-14% body weight loss, approaching but not matching GLP-1 medications
No pills, powders, or messy liquidsjust convenient daily wellness
